Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

August 4, 2023

Study Completion Date

December 30, 2023

Conditions

Posttransplant Diabetes Mellitus

Interventions

DRUG

LCP-tacrolimus

Prophylaxis of transplant rejection in liver and kidney allograft recipients

DRUG

twice-daily tacrolimus

Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients

Trial Locations (1)

University Hospital Tuebingen, Tübingen

All Listed Sponsors

lead

University Hospital Tuebingen

OTHER

NCT05396898 - Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial) | Biotech Hunter | Biotech Hunter